AstraZeneca, Daiichi Sankyo's Enhertu Combination Therapy Recommended for EU Approval in Breast Cancer
MT Newswires Live
Jul 24
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu, in combination with pertuzumab, was recommended for approval in the European Union as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, according to a Friday statement.
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval based on the results of a phase 3 trial, in which the combination therapy reduced the risk of disease progression or death by 44% versus taxane, trastuzumab and pertuzumab (THP) treatment, Daiichi Sankyo said.
The European Commission will now review the recommendation, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.